Key Points
- Director Brian Posner purchased 3,000 shares of Dyne Therapeutics on March 6 at an average price of $15.06, boosting his stake by 35.29% to 11,500 shares (about $173,190); the transaction was disclosed in an SEC filing.
- Shares traded up 11.8% and opened at $19.78, as the company carries a $3.26 billion market cap, negative earnings (quarterly EPS of -$0.76 missed estimates), and analysts forecast a -3.44 EPS for the year.
- Analyst and institutional backdrop: Dyne has a consensus "Moderate Buy" rating with a $36.13 target, mixed analyst price targets, and very high institutional ownership (about 96.68%), with several firms recently increasing positions.
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Brian Posner acquired 3,000 shares of the business's stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average cost of $15.06 per share, with a total value of $45,180.00. Following the completion of the acquisition, the director owned 11,500 shares in the company, valued at $173,190. This trade represents a 35.29% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Dyne Therapeutics Trading Up 11.8%
Shares of DYN stock opened at $19.78 on Wednesday. The stock has a market capitalization of $3.26 billion, a price-to-earnings ratio of -5.59 and a beta of 1.34. The company's fifty day simple moving average is $17.02 and its two-hundred day simple moving average is $17.20. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $25.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.02). As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms have weighed in on DYN. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dyne Therapeutics in a report on Wednesday, January 21st. TD Cowen reaffirmed a "buy" rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Raymond James Financial reaffirmed a "strong-buy" rating and set a $40.00 target price on shares of Dyne Therapeutics in a report on Monday, December 8th. JPMorgan Chase & Co. lowered their target price on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 20th. Finally, HC Wainwright reduced their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating for the company in a research report on Tuesday, March 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Dyne Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $36.13.
Check Out Our Latest Stock Report on DYN
Institutional Trading of Dyne Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC purchased a new position in Dyne Therapeutics in the first quarter worth $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Dyne Therapeutics by 5.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company's stock worth $597,000 after purchasing an additional 2,886 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company's stock worth $10,407,000 after purchasing an additional 366,183 shares in the last quarter. Caxton Associates LLP bought a new position in shares of Dyne Therapeutics during the 1st quarter valued at about $157,000. Finally, Teacher Retirement System of Texas raised its holdings in shares of Dyne Therapeutics by 20.3% during the 2nd quarter. Teacher Retirement System of Texas now owns 19,700 shares of the company's stock valued at $188,000 after buying an additional 3,320 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
